1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Biocon Limited

Biocon Limited

323.50
INR
-6.80
(-2.06%)
2.84EPS
123.03P/E
681.70BMarket Cap
Nov 05Next Earn
Biocon Limited
NSE:BIOCON
(National Stock Exchange of India)

Recent

price

323.50

P/E

ratio

123.03

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
15.25
17.43
20.65
24.22
25.49
27.66
32.65
33.72
45.47
51.89
59.03
67.37
91.64
118.75
125.7
122.82
118.14
Revenue per Share
2.9
2.88
4.33
3.51
4.14
4.67
5.2
3.16
7.65
6.32
6.24
5.44
3.88
8.55
8.46
2.82
3.4
Basic EPS, GAAP
4.76
2.26
0.94
-2.02
-5.88
-3.68
-1.04
-2.16
-2.85
-4.67
-4.94
-6.28
1.06
8.55
14.35
0.6
- -
Free Cash Flow per Basic Share
0.6
0.77
0.85
1.49
1
1.87
- -
0.67
0.67
0.59
- -
- -
0.6
1.7
0.69
0.66
- -
Dividend per Share
16.94
18.94
22.46
25.22
27.19
33.62
40.31
43.17
50.82
55.88
63.56
70.68
149.64
165.3
180.66
210.14
- -
Book Value per Share
14.99
17.91
21.38
24.02
25.34
31.56
37.16
38.23
43.9
46.97
53.56
59.66
-73.66
-57.45
-45.19
32.25
- -
Tangible Book Value per Share
1,173
1,175
1,175
1,177
1,200
1,178
1,178
1,180
1,183
1,184
1,187
1,191
1,193
1,195
1,197
1,366
1,457
Basic Weighted Avg Shares
17,898
20,490
24,263
28,513
30,592
32,580
38,458
39,781
53,811
61,448
70,074
80,248
109,341
141,958
150,522
167,799
172,116
Sales/Revenue/Turnover
20.75
16.77
16.31
17.83
16.17
16.25
18.34
11.17
17.65
17.13
13.64
14.79
14.88
10.11
10.8
10.26
8.64
Operating Margin (%)
1,567
1,758
1,793
2,036
2,210
2,487
2,772
3,851
4,478
5,522
7,151
8,142
11,131
15,688
16,870
19,567
20,491
Depreciation Expense
3,399
3,384
5,089
4,138
4,974
5,504
6,121
3,724
9,053
7,482
7,405
6,484
4,627
10,225
10,133
3,856
4,953
Net Income, GAAP
14.71
13.78
15.98
19.88
15.33
18.93
19.02
25.72
17.47
25.94
20.75
21.51
28.32
14.91
24.23
17.66
13
Effective Tax Rate (%)
18.99
16.52
20.97
14.51
16.26
16.89
15.92
9.36
16.82
12.18
10.57
8.08
4.23
7.2
6.73
2.3
2.88
Profit Margin (%)
7,466
9,839
12,501
12,592
8,776
23,052
23,694
20,073
18,500
13,170
33,903
45,543
38,233
-1,796
19,524
31,106
- -
Working Capital
74
244
1,316
5,868
7,671
20,724
21,082
17,898
15,407
13,053
30,757
42,200
154,996
134,248
129,445
112,833
- -
LT Debt
20,705
22,762
27,599
31,090
33,743
42,996
52,138
56,485
67,069
73,831
85,076
94,700
224,888
252,748
277,125
366,215
- -
Total Equity
13.47
12.11
18.11
11.66
11.93
9.79
7.89
4.23
10.95
8.52
7.58
6.19
3.97
4.73
4.75
2.12
- -
Return on Invested Capital (%)
14.85
14.14
18.5
11.46
11.1
9.01
7.8
4.41
10.17
7.01
5.9
4.19
2.11
3.84
2.9
2.44
- -
Return on Capital (%)
17.93
15.72
20.49
14.47
15.82
15.09
13.8
7.43
16.05
11.69
10.33
8.08
3.52
5.43
4.89
1.39
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
41,508
- -
LT Borrowings
- -
107,463
- -
LT Finance Leases
- -
5,370
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,337
1,620
1,630
Market Capitalization
526,630
584,480
681,701

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
171,798
- -
Cash, Cash Equivalents & STI
- -
40,426
- -
Accounts Receivable, Net
- -
59,868
- -
Inventories
- -
60,857
- -
Total Current Liabilities
- -
140,692
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
41,508
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.66%
40.59%
32.15%
Free Cash Flow
73.28%
118.71%
-95.21%
Net Income, GAAP
11.38%
3.41%
-61.95%
Sales/Revenue/Turnover
18.31%
19.62%
11.48%
Total Cash Common Dividend
- -
- -
9.53%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
33,761
35,450
38,214
43,581
150,522
2026
39,101
42,625
41,730
44,843
167,799
2027
42,918
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.51
-0.13
0.21
2.88
8.46
2026
0.26
0.66
1.08
0.79
2.82
2027
0.87
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.69
2026
- -
- -
- -
- -
0.66
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Biocon Limited, India's largest biopharmaceutical company headquartered in Bengaluru and founded in 1978 by Kiran Mazumdar-Shaw, develops, manufactures and markets a broad portfolio of generics, biosimilars, novel biologics and branded formulations; its core offerings encompass active pharmaceutical ingredients including cardiovascular, anti-diabetics, immunosuppressants, statins, anti-cancer, anti-fungal and multiple sclerosis therapies; biosimilar insulins such as INSUGEN and BASALOG, monoclonal antibodies like BIOMAb EGFR, CANMAb, ALZUMAb and KRABEVA, alongside formulations in metabolics, oncology, immunotherapy and nephrology including Evertor, TACROGRAF and BLISTO; and contract research services through its listed subsidiary Syngene International. The company operates manufacturing facilities in Bengaluru and Malaysia, with products sold in over 120 countries encompassing the United States, Europe, Japan, Australia and emerging markets including India. Biocon Biologics, its biosimilars subsidiary in which it holds a 90.2% stake, drives much of its advanced biologics pipeline. In recent developments, Biocon Biologics expanded its partnership with Civica in 2025 to launch private-label insulin glargine in the United States; the company raised ₹4,500 crore through a qualified institutional placement in June 2025 to bolster its Biocon Biologics stake and facilitate private equity exits; it explores a potential merger of Biocon Biologics valued at $4.5 billion advised by Morgan Stanley to streamline operations and enhance shareholder value; Biocon announced partnerships such as with Tabuk Pharmaceuticals for commercialization and the acquisition of Eywa Pharma's manufacturing facility as of December 2025; and earlier integrated Viatris' global biosimilars business acquired in 2022 for $3.34 billion.

Company News

Company News APIChatGPT

  • prnewswire.com

    Shreehas Tambe nombrado CEO y Director General de Biocon Limited con efectos a partir del 1 de abril de 2026

  • prnewswire.com

    Shreehas Tambe übernimmt zum 1. April 2026 die Rolle des Executive Officer und Managing Director bei Biocon Limited